PF-07104091 hydrate
目录号 : GC62661PF-07104091 hydrate是一种强效且选择性的 CDK2/E1 和 GSK3β 抑制剂,其 Ki 值分别为 1.16 和 537.81 nM。PF-07104091 水合物对细胞周期蛋白 E1 扩增的癌症具有抗肿瘤活性,常用于治疗 HR+/HER2- 乳腺癌和卵巢癌。
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines | OVCAR3 |
Preparation Method | OVCAR3 cells were treated with (37-3000) nM PF-07104091 for 24 hours. |
Reaction Conditions | PF-07104091(37、111、333、1000、3000) nM;24h |
Applications | PF-07104091 inhibits the expression of biomarkers t-Rb, t-NCL, pRB S8078/811, and p-NCL T84 in OVCAR3 cells. |
Animal experiment [1]: | |
Animal models | ovarian cancer modle |
Preparation Method | OVCAR3 tumors in mice treated with PF-07104091 orally (PO) twice per day (BID) for 25 day. |
Dosage form | PF-07104091 (25、75、175)mpk;25 day; twice per day;PO |
Applications | Tumor growth inhibition (TGI) profile of OVCAR3 tumors in mice treated with PF-07104091 orally (PO) twice per day (BID). |
References: |
PF-07104091 hydrate is a potent and selective inhibitor of CDK2/E1 and GSK3β with Kis of 1.16 and 537.81 nM[1], respectively. PF-07104091 hydrate has antitumor activity against cyclin E1-amplified cancers and is commonly used to treat HR+/HER2- breast cancer and ovarian cancer[2].
PF-07104091 (37-3000nM, 24h) inhibits the expression of biomarkers t-Rb, t-NCL, pRB S8078/811, and p-NCL T84 in OVCAR3 cells[1].PF-07104091(0.01-10mM, 3day) inhibits the proliferation of tumor cells (TOV-21G, HCT116) [3].
PF-07104091 (25、75、175 mpk,25 day; twice per day;PO) inhibits tumor growth (TGI) of OVCAR3 tumors mice[1] .In nude mouse model of HCT116 transplanted tumor, PF-07104091(50 mg/kg, 14 day) reduced tumor volume by nearly 69.81% and tumor weight by nearly 60.16%.[3]
References:
[1].Shen C, Zhang Q, Almaden J, et al. PF-07104091, a first-in-class CDK2-selective inhibitor for the treatment of HR+/HER2-breast cancer and CCNE1 high ovarian cancer[J]. Cancer Research, 2024, 84(6_Supplement): 5709-5709.
[2]. Douglas Carl BEHENNA, et al. Cdk2 inhibitors. WO2020157652A2.
[3]. Liu, Z.; Yang, Y.; Sun, X.; Ma, R.; Zhang, W.; Wang, W.; Yang, G.; Wang, H.; Zhang, J.; Wang, Y.; et al. Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53. Molecules 2024, 29, 725.
PF-07104091 hydrate是一种强效且选择性的 CDK2/E1 和 GSK3β 抑制剂,其 Ki 值分别为 1.16 和 537.81 nM[1]。PF-07104091 水合物对细胞周期蛋白 E1 扩增的癌症具有抗肿瘤活性,常用于治疗 HR+/HER2- 乳腺癌和卵巢癌[2]。
PF-07104091(37-3000nM,24小时)抑制OVCAR3细胞中生物标志物t-Rb,t-NCL,pRB S8078/811和p-NCL T84的表达[1]。PF-07104091(0.01-10mM,3day)抑制肿瘤细胞(TOV-21G,HCT116)的增殖[3]。
PF-07104091(25、75、175 mpk,25 天;PO)抑制OVCAR3肿瘤小鼠的肿瘤生长(TGI)。在HCT116裸鼠模型中,PF-07104091(50 mg/kg,14天)使肿瘤体积减少了近69.81%,肿瘤重量减少了近60.16%[3]。
Cas No. | SDF | ||
分子式 | C19H30N6O5 | 分子量 | 422.48 |
溶解度 | 储存条件 | 4°C, away from moisture and light | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.367 mL | 11.8349 mL | 23.6698 mL |
5 mM | 0.4734 mL | 2.367 mL | 4.734 mL |
10 mM | 0.2367 mL | 1.1835 mL | 2.367 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。